Seres Therapeutics Inc (NASDAQ: MCRB): Time To Buy Over The Next Few Months

In the last trading session, 2.1 million Seres Therapeutics Inc (NASDAQ:MCRB) shares changed hands as the company’s beta touched 1.97. With the company’s per share price at $0.71 changed hands at $0.0 or -0.30% during last session, the market valuation stood at $107.27M. MCRB’s last price was a discount, traded about -781.69% off its 52-week high of $6.26. The share price had its 52-week low at $0.54, which suggests the last value was 23.94% up since then. When we look at Seres Therapeutics Inc’s average trading volume, we note the 3-month average coming to 4.82 million.

Seres Therapeutics Inc (NASDAQ:MCRB) trade information

Instantly MCRB was in red as seen at the end of in last trading. With action 15.36%, the performance over the past five days has been green. The drop to weekly highs of 0.9292 subtracted -0.30% to the stock’s daily price. The company’s shares are showing year-to-date downside of -49.41%, with the 5-day performance at 15.36% in the green. However, in the 30-day time frame, Seres Therapeutics Inc (NASDAQ:MCRB) is -26.06% down.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Seres Therapeutics Inc (MCRB) estimates and forecasts

Data shows that the Seres Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -32.54% over the past 6 months, a -15.73% in annual growth rate that is considerably lower than the industry average of 15.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.22%. The 2024 estimates are for Seres Therapeutics Inc earnings to decrease by -17.43%.